For investors and partners
AKIGAI is preparing for funding to advance one of our identified development candidates to a phase II trial.
We are looking for investors who can bring experience in drug development and in partnering with larger pharmaceutical companies, to the table.
Partnerships
AKIGAI is open for partnership models with companies that are interested in
- developing new drugs against neuropathic pain
- out-license EGFR-inhibitors to AKIGAI
- developing EGFR-inhibitors against neuropathic pain together with AKIGAI.
The partnership model would depend on our mutual interests and the specific EGFR-inhibitor.
We are proud to be
working with
Startuplab
Startuplab is an incubator and early stage investor for Norway's most ambitious technology startups.
Sørlandet Sykehus
Regional hospital in Southern Norway. The first observation of neuropathic pain relief was made and reported by oncologists at Sorlandet Hospital Trust. Since then, Sorlandet Hospital has continuously facilitated and supported research and development initiatives to bring EGFR-inhibitors to patients suffering from neuropathic pain.
Møsbu AS
Gunnar Evensen is currently Board Chairman and investor in a number of technology companies. He has a degree in business administration and has worked as a top executive in Norwegian business and industry for many years.